(Q35559932)

8 August 2017

title

Therapeutic silencing of KRAS using systemically delivered siRNAs (English)

1 reference

8 August 2017

Kshipra M Gharpure

13

0 references

Archana S. Nagaraja

Archana S Nagaraja

11

0 references

Rajesha Rupaimoole

Rajesha Rupaimoole

5

0 references

Rajat Bhattacharya

Rajat Bhattacharya

Cristian Rodriguez-Aguayo

7

0 references

Cristian Rodriguez-Aguayo

10

0 references

Anil K. Sood

21

Anil K Sood

1 reference

8 August 2017

Chad V Pecot

1

1 reference

8 August 2017

Sherry Y Wu

2

1 reference

8 August 2017

Seth Bellister

3

1 reference

8 August 2017

Justyna Filant

4

1 reference

8 August 2017

Takeshi Hisamatsu

6

1 reference

8 August 2017

Anshumaan Maharaj

8

1 reference

8 August 2017

Salma Azam

9

1 reference

8 August 2017

Maria Pia Morelli

12

1 reference

8 August 2017

Trent A Waugh

14

1 reference

8 August 2017

Vianey Gonzalez-Villasana

15

1 reference

8 August 2017

Behrouz Zand

16

1 reference

8 August 2017

Heather J Dalton

17

1 reference

8 August 2017

Scott Kopetz

18

1 reference

8 August 2017

Gabriel Lopez-Berestein

19

1 reference

8 August 2017

Lee M Ellis

20

1 reference

8 August 2017

publication date

3 October 2014

1 reference

Molecular Cancer Therapeutics

8 August 2017

published in

1 reference

8 August 2017

volume

13

1 reference

8 August 2017

issue

12

1 reference

8 August 2017

page(s)

2876-2885

1 reference

describes a project that uses

8 August 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4416486/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

cites work

Tumour angiogenesis regulation by the miR-200 family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Hallmarks of Cancer: The Next Generation

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

RNA interference in the clinic: challenges and future directions

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Ras signaling and therapies

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Dual targeting of EphA2 and FAK in ovarian carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

CellProfiler: free, versatile software for automated biological image analysis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Cancer metastasis: building a framework

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Targeting RAS signalling pathways in cancer therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Isolation of a transforming sequence from a human bladder carcinoma cell line

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Oncogenic K-ras "addiction" and synthetic lethality

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

RAS oncogenes: the first 30 years.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4416486

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25281617

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1535-7163.MCT-14-0074

1 reference

8 August 2017

1 reference

8 August 2017

1 reference